用于糖尿病和肥胖症的GLP-1型药物正被健康的人滥用以获取能量和关注焦点,这引起了安全问题。 GLP-1 drugs, meant for diabetes and obesity, are being misused by healthy people for energy and focus, sparking safety concerns.

最初为2型糖尿病和肥胖症核准的GLP-1药品,在能源、重点和胃口控制得到改善的报道的推动下,非超重者越来越多地使用无标签药品。 GLP-1 medications, originally approved for type 2 diabetes and obesity, are seeing increased off-label use by people who are not overweight, driven by reports of improved energy, focus, and appetite control. 虽然在临床人口中对体重和血糖管理有效,但其对健康人的长期安全尚不清楚,引起医务专业人员对恶心、胰腺炎和过度使用等副作用的关切。 While effective for weight and blood sugar management in clinical populations, their long-term safety in healthy individuals remains unclear, raising concerns among medical professionals about side effects like nausea, pancreatitis, and overuse. 专家强调,这些药物只应在医疗监督之下使用,不是为了增进健康或提高性能。 Experts stress these drugs should only be used under medical supervision and are not intended for wellness or performance enhancement.